Nurix Therapeutics, Inc.

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC NRIX

Report date

12/31/2025

Quarter

2025 Q4

Filed

2/13/2026

Shares

168,843

Value ($000)

3,203

Weight

0.0%

2021 Q2 - 2025 Q4 (17 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2025 Q4	2/13/2026	3,203	0.0%	168,843	12/31/2025
2025 Q3	11/14/2025	907	0.0%	98,145	9/30/2025
2025 Q2	8/14/2025	2,643	0.0%	232,055	6/30/2025
2025 Q1	5/19/2025	1,895	0.0%	159,530	3/31/2025
2024 Q4	2/14/2025	2,764	0.0%	146,713	12/31/2024
2024 Q3	11/14/2024	2,888	0.0%	128,524	9/30/2024
2024 Q2	8/14/2024	2,685	0.0%	128,671	6/30/2024
2023 Q3	11/13/2023	1,891	0.0%	240,608	9/30/2023
2023 Q2	8/11/2023	2,191	0.0%	246,711	6/30/2023
2023 Q1	5/15/2023	2,191	0.0%	246,711	3/31/2023
2022 Q4	2/14/2023	2,696	0.0%	245,496	12/31/2022
2022 Q3	11/14/2022	3,005	0.0%	230,592	9/30/2022
2022 Q2	8/12/2022	3,095	0.0%	244,305	6/30/2022
2022 Q1	5/16/2022	3,548	0.0%	253,272	3/31/2022
2021 Q4	2/14/2022	8,074	0.0%	278,890	12/31/2021
2021 Q3	11/15/2021	8,572	0.0%	286,099	9/30/2021
2021 Q2	8/16/2021	7,584	0.0%	285,880	6/30/2021